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Introduction
Thrombopoietin (TPO) (also called MGDF) has been recently isolated as the ligand for the c-mpl proto-oncogene (Mpl-L). [1] [2] [3] [4] This hematopoietic growth factor appears as the homeostatic regulator of platelet production. Indeed, homozygous TPO or c-mpl knock-out mice exhibit a profound but not lethal thrombocytopenia. 5, 6 In vitro and in vivo experiments have shown that TPO is the most potent growth factor for megakaryocyte (MK) differentiation, acting on different developmental stages including MK progenitors, promegakaryoblasts and MK. 7, 8 Daily TPO injection to animals including mice and primates increased platelet count up to 10-fold the control value in a few days. 9, 10 In addition, it has been shown that in animals TPO is able to accelerate platelet recovery after myeloablative chemotherapy. 11 Therefore, TPO might be a potent therapeutic agent for life-threatening thrombocytopenic episodes associated with chemotherapy or bone marrow transplantation. TPO could also be a therapeutic agent in chronic thrombocytopenia due to platelet destruction. Indeed, it has been shown that TPO serum level is low in immune thrombocytopenic purpura (ITP). This may be due to the clearance of TPO by increased numbers of MK and young platelets 12 since TPO synthesis in the liver and the kidney is not modified by a decrease in the platelet mass. 13, 14 This implies that platelet production may be limited by the endogenous TPO synthesis.
An alternative approach to daily TPO injection could be TPO delivery by gene transfer. The use of a retroviral vector to transfer TPO cDNA into murine stem cells led to a sustained expression of TPO which induced an elevation of the platelet count but also a myelofibrosis and an osteosclerosis. 15 Recently, we have shown that a similar strategy resulted in an even more severe myelofibrosis which led to pancytopenia and, in rare cases, to leukemia. Therefore, the disease induced by a prolonged hyper-498 production of TPO mimics the human idiopathic myelofibrosis. 16 An alternative stategy to retroviral transfer could be the use of an adenoviral vector. Recombinant adenoviruses are now widely used for gene transfer in animal models and also in some clinical protocols. Adenovirus is a DNA virus capable of efficiently transducing a wide range of cell types in vitro and in vivo. 17 It has been used for the delivery of erythropoietin (Epo) cDNA 18, 19 and more recently for TPO in mice. 20 It has been demonstrated that in vivo gene transfer with an adenovirus vector resulted in a lower Epo production than in experiments using a retroviral vector to transduce hematopoietic cells ex vivo. 18, 21 In addition, adenovirus gene transfer is transient due both to the extra-chromosomal delivery of the genetic material and to the immunological clearance of transduced cells. The cellular immunity directed against viral antigen expressing cells was initially thought to be the major mechanism that limits the duration of the transduced gene expression. 22 Recently, several groups have demonstrated that the immune response against the transgene-encoded protein plays an important role in short-term gene expression. [23] [24] [25] However, immunosuppression, even if transient, could lead to sustained expression of the transgene-encoded protein.
We, hereby, demonstrate that a single injection of a recombinant adenovirus containing the human TPO cDNA is able to induce a sustained platelet elevation associated with a myelofibrosis in immunodeficient SCID mice. In contrast, in immunocompetent mice, TPO production is transient. Delivery of human TPO by an adenovirus vector 1 week before a myeloablative regimen protects mice against secondary side-effects due to the regimen which includes 5 Gy irradiation and injection of carboplatin. Survival is essentially due to the wide-range TPO effects on the hematopoietic system, but also likely to the synthesis of inflammatory cytokines in response to the adenovirus infection. However, after myeloablation, a prolonged expression of the transgene-encoded protein was observed.
Results

Administration of AdRSVhuTPO to SCID mice
To evaluate the risk of sustained expression due to immunosuppression, two doses, 10 9 plaque-forming units (p.f.u.) (n = 2) or 5 × 10 9 p.f.u. (n = 2) of AdRSVhuTPO were intravenously injected into immunodeficient SCID mice. Both doses increased platelet count, which peaked at week 4 with a 7.8-and 6.1-fold increase in comparison to the controls (Figure 1 ). These results suggest that the maximum stimulation of the megakaryocytopoiesis requires 4 weeks to amplify megakaryocytic progenitors and platelets. It cannot be excluded that TPO acts first on megakaryocyte progenitors and then on more primitive progenitors. One mouse injected with 10 9 p.f.u. was analyzed at week 6 and still had a 5.5-fold increase in platelet count. Platelets had a normal size in flow cytometry and CD62, a platelet activation marker, was almost undetectable on the platelet surface as it was for platelets from control mice. Despite the absence of constitutively activated platelets, the mice with a high platelet count had no spontaneous thrombosis but some mice died (one in each group) suddenly during the blood puncture, probably from a massive thrombosis. This was suggested by the absence of bleeding from the retro-orbital sinus and sudden death. A decrease in the hematocrit values was observed, a two-fold decrease at week 4 for the survival mouse injected with 5 × 10 9 p.f.u. and 1.3-fold decrease at week 6 for the survival mouse injected with 10 9 p.f.u. The leukocyte count showed a six-fold increase at week 6 for the mouse injected with 10 9 p.f.u. Histological analysis of tissues from SCID mice prepared 2 weeks after AdRSVhuTPO injection revealed a marked MK hyperplasia in the liver, spleen and bone marrow. Rare MK were also observed in the lung. At week 6, a similar widespread MK infiltrate was observed. Mature myeloid precursor cells were increased in the bone marrow, spleen, liver and the lung. The Gordon Sweet staining revealed a myelofibrosis and a spleen fibrosis, with a neoosteogenesis in the marrow (Figure 2a-d) .
Analysis of huTPO in the sera of the injected mice, using a biological assay on the Ba/F3-hu-mpl cells, showed a dose-dependent production. The 5 × 10 9 p.f.u.-injected mice had 0.5-1 g/ml, 1-1.2 g/ml, 0.4 g/ml of huTPO at 2, 3 and 4 weeks, respectively, while the 10 9 p.f.u.-injected mice had 1-2 ng/ml, 0.1 g/ml, 0.2 g/ml, 0.1 g/ml at 2, 3, 4 and 6 weeks, respectively.
Administration of AdRSVhuTPO to normal DBA/2J mice
Platelet production: A second set of experiments was performed to evaluate the effects of intravenous administration of AdRSVhuTPO to immunocompetent DBA/2J mice. In two independent experiments, the injection of 4-6 × 10 9 p.f.u. of AdRSVhuTPO led to a 1.3-to 1.8-fold (263 ± 31 × 10 4 /l, n = 13) increase in the platelet count 1 week after inoculation (P Ͻ 0.001), and a 1.8-to 3.5-fold (411 ± 74 × 10 4 /l, n = 11) increase in the second week (P Ͻ 0.001) (Figure 3 ). During the third week, platelet a b c d
Figure 2 Histological examination of organs from SCID mice 6 weeks after intravenous injection of AdRSVhuTPO. (a) Sustained megakaryocyte hyperplasia in liver (original magnification × 250). (b) Neo-osteogenesis in bone marrow cavity (original magnification × 40). (c) Reticulin fiber densification in bone marrow (original magnification × 250) and (d) fibrosis in the spleen (original magnification × 400).
count decreased (192 ± 138 × 10 4 /l, n = 13) and returned to pretreatment level (P Ͻ 0.30). Two mice that had the highest platelet count at week 3 and also at week 4 died at that time with a massive thrombosis following blood puncture. At week 4 the mean platelet count was normal (157 ± 115 × 10 4 /l) (n = 13, P Ͻ 0.80). At that time an antibody response against TPO was shown to neutralize the biological activity of this hormone. The antibody response against TPO was determined by ELISA and the neutralizing activity of the antibodies was determined on the human and murine c-mpl-transfected Ba/F3 cell line.
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TPO level in the sera of DBA/2J mice: TPO serum levels were measured weekly by a biological assay after the injection of 4-6 × 10 9 p.f.u. of AdRSVhuTPO. During the first week, TPO level increased to 50-400 ng/ml. Thereafter, the TPO level rapidly declined to 1.2-6.4 ng/ml in the second and third week and then returned to undetectable levels after 4 weeks. 
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Histological analysis: At week 2, the liver of AdRSVhuTPO-and AdRSV␤gal-injected DBA/2J mice exhibited mononuclear and polymorphonuclear cell granuloma in the lobular area around focal necrosis. This histological aspect of the liver corresponds to the infiltrative and inflammatory response to adenovirus, as previously described after the intravenous injection of adenovirus vector in immunocompetent mice. 22 Liver, spleen and bone marrow sections of AdRSVhuTPO-injected mice revealed a megakaryocytic hyperplasia, which was particularly evident on bone marrow sections. Four weeks after injection, liver, spleen and bone marrow had a normal aspect as observed in the control mice.
Administration of AdRSVhuTPO to DBA/2J mice after myeloablative treatment Finally, we investigated whether the injection of AdRSVhuTPO in mice treated with a myeloablative regimen would reduce the thrombocytopenia and protect these animals from secondary side-effects in the aplastic period.
Kinetics of hematological parameters after a myeloablative regimen: A 5 Gy irradiation combined with an intraperitoneal injection of 1.2 mg of carboplatin was given to control mice (PBS) and to mice 1 week following the injection of 6 × 10 9 p.f.u. of AdRSVhuTPO or AdRSV␤gal. One week later, the AdRSVhuTPO-injected mice had 30% normal platelet values while the AdRSV␤gal and the PBS-injected mice had 20% normal platelet values. After 2 weeks, platelet counts continued to decrease in the three groups of mice reaching 2-5% of the baseline level. After 3 weeks, in the AdRSVhuTPOinjected mice, platelet counts progressively increased to reach normal levels at week 6 post-regimen (Figure 4a ). Two mice were followed for a long time and platelet counts continued to increase to reach 2.3-fold the normal level at week 10. The platelet count was then stable at that level for at least 5 months following the initial injection.
White blood cell (WBC) counts and hematocrit levels were also monitored in the three groups (Figure 4b and c). WBC count decreased in parallel in the three groups, reached a similar nadir at week 2, but was slightly more elevated (2.3-and six-fold the WBC counts of the AdRSV␤gal-and the PBS-injected mice, respectively) in the AdRSVhuTPO-injected mice at week 3.
The kinetics of the hematocrit showed a slight decrease in the AdRSVhuTPO-injected mice, 80 and 77% of normal values at weeks 1 and 2 post-regimen, respectively. At week 3, hematocrit values returned to baseline level. In contrast, the AdRSV␤gal-or PBS-injected mice had a profound decrease in hematocrit values, being respectively 48 and 25% of the normal level at week 2.
As shown in Figure 4d , all control mice (AdRSV␤gal-and the PBS-injected mice) did not survive for more than 3 weeks (n = 16). In contrast, seven of eight AdRSVhuTPO-injected mice survived the myeloablative treatment.
Upon necropsy, we did not observe any evident diffuse hemorragia which could account for the premature death of the control animals, therefore we analyzed the cause of death. We performed Gram staining and bacterial cultures of various organs (spleen, lung, liver), blood and feces of moribund mice. It could be determined that mice probably died from septicemia due to Enterobacteria cloacae which were present in blood and the different organs cited above but not in their feces, suggesting an environmental contamination. Because of this observation, we performed another experiment in which animals were maintained in sterile conditions, without any manipulation. In this experiment, none of the AdRSVhuTPO-, AdRSV␤gal-or PBS-injected mice died during the 6 weeks of follow-up. These data indicate that a single AdRSVhuTPO injection is able to protect myelosuppressed mice efficiently from bacterial environmental infections.
TPO level in the sera of DBA/2J mice after myeloablative regimen: Mice subjected to the myeloablative regimen had a stable TPO level during the 3 weeks following the regimen, contrasting with what was observed in nonaplastic mice. The TPO mean level was 5.2 ng/ml at week 2, 5.5 ng/ml at week 3, 6.4 ng/ml at week 4 and 38.4 ng at week 5 following AdRSVhuTPO injection. Two AdRSVhuTPO-injected mice were followed until 4 months for huTPO production, one mouse having 2 ng/ml and the other 20 ng/ml. As shown above, these two mice had, at that time, about two-fold the normal platelet count.
Analysis of committed progenitors after the myeloablative regimen: CFU-MK, CFU-GM and BFU-E-derived colonies were analyzed at weeks 1, 2 and 3 after the myeloablative regimen. A rapid decline in the number of marrow CFU-MK (Figure 5a ), CFU-GM (Figure 5b ) and BFU-E (Figure 5c ) was observed and these progenitors were barely detectable at weeks 1 and 2 in the three groups of animals. At week 3, their number began to increase but with marked differences between the AdRSVhuTPO-, AdRSV␤gal-and PBS-injected mice. AdRSVhuTPOinjected mice had 41, 7 and 11% of the normal values for marrow CFU-MK, CFU-GM and BFU-E which respectively corresponded to a 2.4-, 10-and 70-fold increase in comparison to PBS-injected mice. The number of CFU-MK in AdRSV␤gal-or PBS-injected mice at week 3 was much lower than the number of AdRSVhuTPO-injected mice (19 and 18.5%, of the normal values, respectively). At the same time, CFU-GM and BFU-E progenitor cells in AdRSV␤gal-or PBS-injected mice had 2.3 and 0.7% respectively, of normal CFU-GM values and 6.5 and 0.1%, respectively, of normal BFU-E values.
As seen above, the CFU-GM-and BFU-E-derived colony numbers of the AdRSV␤gal-injected mice were 3.4-and 40-fold increased, respectively, in comparison to the PBS-injected mice, while the number of CFU-MK was similar.
Discussion
The studies performed here had two goals: first, to compare the effects of TPO overexpression in immunodeficient and immunocompetent mice injected with an adenovirus vector encoding the human TPO molecule; and second, to evaluate the efficacy of gene therapy by TPO in a myeloablative regimen. The results demonstrate that a single intravenous injection of AdRSVhuTPO in immunodeficient SCID mice induced a prolonged thrombocytosis associated with myelofibrosis and extramedullary hematopoiesis. Prolonged expression was also observed following myeloablation. In contrast, the same protocol in immunocompetent DBA/2J mice induces a transient thrombocytosis. Injection of AdRSVhuTPO in DBA/2J mice receiving a myeloablative regimen protected the animals from morbidity, essentially by the action of TPO on the granulo-macrophagic differentiation.
One of the characteristics of gene transduction by first generation adenovirus vectors is a transient expression in immunocompetent hosts. To evaluate the risk of TPO overexpression in immunosuppressed recipients, the AdRSVhuTPO was injected into immunodeficient mice (SCID mice) and the platelet count was monitored. We observed a chronic TPO expression which induced an up
Figure 5 Effects of a single AdRSVhuTPO injection on (a) CFU-MK, (b) CFU-GM and (c) BFU-E numbers in the bone marrow of myelosuppressed DBA/2J mice. Each bar represents the mean ± s.d. total progenitor cell numbers per femur for AdRSVhuTPO-(, n = 3), AdRSV␤gal-(ᮀ, n = 3) and PBS ( , n = 3)-injected mice following the myelosuppressive regimen. At week 3, two mice per group were analyzed. No CFU-MK-derived progenitors were detected at weeks 1 and 2 for each group. For these experiments mice were maintained in sterile conditions without manipulations until the day of death to avoid mortality due to septicemia (see Results section: Kinetics of hematological parameters after a myeloablative regimen).
to eight-fold increase in the platelet count for more than 6 weeks. huTPO levels in the sera of SCID mice were up to 1.2 g/ml at week 2 after adenovirus injection, and one mouse analyzed at 6 weeks still had 0.1 g/ml. As previously demonstrated by Yan et al 15, 26 using retrovirus vectors, TPO overexpression by means of adenovirus also induced a myelofibrosis associated with osteosclerosis, fibrosis of the spleen and extramedullary hematopoiesis. The myelofibrosis had some repercussions on blood cell counts as shown by anemia and leukocytosis. In a recent report from our laboratory using a similar approach to that performed by Yan et al, 15, 26 mice infected with a TPO retroviral vector developed a lethal myelofibrosis with pancytopenia within 4 months. 16 More recently, transgenic mice overexpressing TPO have been obtained that exhibited a chronic thrombocytosis without myelofibrosis. 27 It was hypothesized that the differences between the retroviral models and the transgenic mice were related to the differences in cells producing TPO. 27 Indeed, in the transgenic animals, TPO is synthesized by the liver whereas in the retroviral model TPO is expressed by marrow cells. The present model has many similarities with the transgenic model. 27 Intravenous injection of the adenovirus results in targeting mainly liver cells and at a lower extent endothelial cells, and in both studies the human TPO cDNA was used. 27 However, transduction of the TPO cDNA with the adenoviral vector led to a myelofibrosis. In fact, there is increasing evidence that the differences in the severity of the disease are related to the level of TPO synthesis. In SCID mice injected with AdRSVhuTPO, plasma TPO levels are extremly high, 0.1-1 g/ml as determined by a biological assay, similar to that obtained in the model described by Villeval et al 16 which leads to a lethal disease. In the other models, plasma TPO levels are much lower, from almost undetectable by biological assay 26 to 3 ng/ml in an ELISA assay. 27 It must be emphasized that the TPO plasma level is certainly not the direct reflection of the TPO synthesis in these different models. Indeed, it is likely that the increase in platelets and MK in response to increased TPO synthesis might be sufficiently high to take up and clear the entire TPO produced in most models. The differences presently observed in TPO serum levels between animals untreated or treated by a myeloablative regimen are certainly explained by this mechanism. The hypothesis that differences in the severity of the disease are related to the level of TPO hyperproduction is further sustained by the fact that only high-dose injection of pegylated megakaryocyte growth and development factor (PEG-MGDF) in mice induces a myelofibrosis with a decrease in red blood cells. 28 The mechanisms by which TPO induces a myelofibrosis are unknown. It is suggested that myelofibrosis is directly correlated to the MK hyperplasia and that it may be due to the local release of TGF-␤, PDGF and eventually other fibroblast mediators by MK. 15 In favor of this hypothesis, we have not only detected a myelofibrosis but also a fibrosis in the spleen where the extramedullary hematopoiesis takes place. This induction of a myelofibrosis may preclude chronic therapy by TPO, especially if high doses are used. The existence of a myelofibrosis has not yet been described in nonhuman primates treated by TPO. However, it cannot be totally excluded that the induction of myelofibrosis might be species specific.
In addition, transient immunosuppression using immunosuppresive drugs or anti-CD4 antibodies has been shown to induce sustained expression of the transgene-encoded protein after recombinant adenovirus gene transfer. [29] [30] [31] [32] We show that transient immunosuppression may also occur following a myeloablative regimen, and is responsible for a sustained TPO production and high platelet counts. This emphasizes the risk of inducing secondary myelofibrosis and also thrombosis if such a protocol is applied. One possibility of avoiding this problem would be the use of inducible promotors to control the expression of the transgene.
Injection of the AdRSVhuTPO into normal mice induced only a transient expression (3-4 weeks) and was not associated with a myelofibrosis. However, as shown with SCID mice, high platelet counts could also lead to massive thrombosis following blood puncture. Gene therapy of thrombocytopenia from a myeloablative regimen by means of an adenovirus vector has been recently proposed. 20, 33 Especially, it has been shown that a single injection of AdCMVhuTPO can maintain the platelet count but only when a slight reduction has occurred following chemo-radiotherapy. 20 A similar approach has been performed with an Ad.FGF4. 33 However, in these two reports, consequences of immunosuppression were not evaluated since the follow-up of mice was stopped at week 3.
In this study we have explored whether a single intravenous injection of AdRSVhuTPO will protect mice from lethal cytopenia induced by a combination of sublethal irradiation and carboplatin. The same protocol of myelosuppression has been previously used to study the effects of daily administration of PEG-MGDF. 11 As in the previous study, we could show that TPO was able to protect mice from secondary side-effects following myeloablative therapy. Interestingly, we show that the protective effect of TPO is not essentially due to a shortened thrombocytopenic period or a decrease in the nadir, despite the presence of circulating human TPO from week 1 to at least week 5, but to an acceleration in hematopoietic recovery. Hematocrits of AdRSVhuTPO-injected mice only slightly diminished and the duration of neutropenia was shorter. Therefore, control animals died from septicemia but not from widespread bleeding whereas 90% of AdRSVhuTPO-injected mice survived. These effects of TPO may be related to its effects on primitive hematopoietic progenitors. 34, 35 Kinetics analysis of progenitor cells in myelosuppressed mice demonstrate that TPO had a major effect on MK differentiation, and also on the other lineages. The early CFU-GM increase in AdRSVhuTPOinjected mice accelerated neutrophil recovery and protected mice against bacterial infection, while control mice died from septicemia. However, this effect may not be due to TPO alone since administration of an adenoviral vector may lead to the release of inflammatory cytokines such as IL-6 and IL-1, 36,37 which may contribute to the acceleration of hematological recovery. This hypothesis is further sustained by the fact that 3 weeks after myelosuppression AdRSV␤gal-injected mice had a 3.4-fold and 40-fold increase in CFU-GM and BFU-E, respectively, in comparison to PBS-injected mice. In contrast, the numbers of CFU-MK in the two groups were identical.
This study differs from those performed with AdCMVhuTPO 20 or PEG-MGDF 11 administration. In the former study, the nonlethal myeloablative regimen induced only a moderate thrombocytopenia (10-to fivefold reduction in the platelet count) and showed in this case a reduction in the duration of the thrombocytopenia. 20 Our results are therefore difficult to compare with those of Ohwada et al. 20 However, when we used a 3 Gy irradiation protocol, which induces a moderate thrombocytopenia, a single injection of AdRSVhuTPO was able to accelerate platelet recovery (data not shown). Our results are more comparable with those of Hokom et al 11 where daily injection of PEG-MGDF also reduced the mortality induced by this myeloablative regimen. Mortality of these animals was related to widespread bleeding and survival was due to an improvement of the depth and duration of thrombocytopenia. In addition, the severity of leukopenia and anemia were also reduced. Differences between the AdRSVhuTPO and PEG-MGDF administration protocols may be due both to the genetic background of the mice (DBA/2J versus Balb/c), the level of TPO in the animals and to the release of inflammatory cytokines after adenovirus injection. It has to be emphasized that in both cases TPO has a marked effect on the erythroid lineage and almost completely abolishes anemia. This effect might be due both to a direct stimulatory effect of TPO on erythropoiesis, as shown here on the number of BFU-E, and indirectly by the reduction of bleeding.
In humans, PEG-MGDF administration stimulates production of platelets in a dose-dependent manner. 38 In addition, a slight reduction of the thrombocytopenic period, following PEG-MGDF administration, has been demonstrated in patients receiving chemotherapy. The chemotherapy used combined administration of carboplatin and paclitaxel and induced only a slight decrease in the platelet count. 39 In summary, this study shows that a single AdRSVhuTPO intravenous injection is able to induce a 504 sustained thrombocytosis associated with a myelofibrosis in immunodeficient mice. Myelosuppression, by inducing transient immunosuppression, is also able to induce sustained expression. In contrast, in immunocompetent mice, the effect on platelet count is transient (less than 4 weeks) and does not lead to a myelofibrosis. High platelet counts in normal and immunodeficient mice in some cases induced massive thrombosis responsible for their death. The major effects observed in the aplastic period are the reduction of anemia and protection against septicemia which could almost suppress the mortality induced by a myeloablative regimen. However, differences in platelet recovery with other protocols of administration are observed, which emphasizes the importance of precisely determining the doses and time of TPO injection in subsequent clinical studies. The use of adenovirus vector for this goal is conditioned by an efficient control of the expression of the transgene.
Materials and methods
Construction of recombinant E1-deleted adenoviral vector
The human TPO cDNA was inserted into the restriction site EcoRV of the adenovirus (Ad) Rous sarcoma virus (RSV) ␤-galactosidase (␤-gal) plasmid after excision of the ␤-gal gene by SalI. The huTPO cDNA under control of the RSV viral promoter is followed by mu 9.4-17 (BglII-HindIII fragment) of Ad5 to allow homologous recombination for the generation of the recombinant adenovirus. The resulting plasmid was cotransfected into the human embryonic 293 cell line with ClaI-digested Ad5dl324 DNA using precipitation by calcium phosphate as previously described. 40 AdRSV␤gal carrying the nuclear localization site (nls) E. coli lacZ marker gene under the control of the same viral promoter was used as a control and was previously described. 40 Viral stocks were prepared by infection of the 293 cell line, purified and concentrated by a double cesium chloride gradient, dialysed, aliquoted and stored in 10% glycerol at −80°C. Titers of the viral stocks were determined by limited dilution on plaque assays using 293 cells and expressed as p.f.u. per ml.
Animal procedures DBA/2J mice were obtained from Janvier (Orleans, France), SCID/SCID mice were kindly provided by J Dick (Hospital for Sick Children, Toronto, Canada). All the animals were bred in negative pressure isolators for adenovirus injection experiments in the animal facilities of the Institut Gustave Roussy. Female mice (6-8 weeks old) were injected with recombinant adenoviruses in the retro-orbital sinus. DBA/2J mice were injected with 4-6 × 10 TPO concentrations TPO concentrations in the sera of mice were measured using a microwell assay. 41 These assays were performed in duplicate by adding 200 cells from the human c-mpltransfected Ba/F3 cell line 4 in 10 l volume of DMEM plus 10% fetal calf serum (FCS) to serial two-fold dilutions of the serum. TPO concentrations were calculated by assigning 1 U/ml to the concentration resulting in 50% cell survival after 2-3 days incubation. In a doseresponse curve with the full-length recombinant human TPO, 1 U is approximately the equivalent of 100 pg of molecule.
Peripheral hematological parameters
Blood samples were obtained from ether anesthetized animals by punction of the retro-orbital sinus. After red blood cell lysis into Unopette (Becton Dickinson, Franklin Lakes, NJ, USA), platelets and white cells were counted under an optical microscope. Hematocrits were determined by centrifugation of microhematocrit tubes.
Analysis of the activation state of platelets after AdRSVhuTPO injection Platelets generated after AdRSVhuTPO injection in SCID mice were analyzed for their activation state by flow cytometry using entire blood. Blood cells were incubated for 30 min with a FITC anti-CD62 monoclonal antibody (MoAb) (PharMingen, San Diego, CA, USA) and then fixed for 2 h with 0.25 paraformaldehyde. Blood cells were analyzed on a FacSort (Becton Dickinson, Mountain View, CA, USA). The platelet gate was determined by labeling blood cells with the FITC 4A5 MoAb (a generous gift from S Burstein, WK Warren Medical Research Institute, Oklahoma City, OK, USA).
Analysis of committed progenitor cells in the bone marrow and spleen
To determine the number of clonogenic committed progenitor cells, cells from the bone marrow (femur) of DBA/2J mice, taken at different times following injection of AdRSVhuTPO, AdRSV␤gal or PBS, were plated into methylcellulose in the presence of recombinant murine interleukin-3 (r-mu-IL-3) and recombinant human erythropoietin (r-hu-Epo) for CFU-GM and BFU-E. CFU-MK were grown in 0.3% agar supplemented with r-mu-TPO, r-mu-IL-3, recombinant murine stem cell factor (rmu-SCF) as previously described. 4 r-mu-IL-3 and r-mu-SCF were kindly provided by Immunex (Seattle, WA, USA) and used at 100 U/ml and 50 ng/ml, respectively. r-hu-Epo was a gift from Cilag (Paris, France) and was used at 1 U/ml. r-mu-TPO (ZymoGenetics, Seattle, WA, USA) was added at a 10 ng/ml concentration. Bone marrow cells (8 × 10 4 ) were plated in 1 ml of 0.8% methylcellulose in Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% FCS. For CFU-MK determination, bone marrow cells (1 × 10 5 cells) were plated in 500 l agar medium. For each determination, cultures were performed in duplicate at 37°C in a humidified atmosphere of 10% CO 2 in air for 5 days. The mice used in these experiments were maintained in sterile conditions without any manipulations until the day of death (see Results: Kinetics of hematological parameters after a myeloablative regimen).
Histology
Organs (spleen, femur, tibia, kidney, liver and lung) of mice killed at different times after the injection of the recombinant adenovirus vectors were fixed in Bouin or buffered formaldehyde and embedded in paraffin. Thin sections (3-5 m) were stained with hematoxylin/eosin (HE), May-Grü nwald-Giemsa, periodic acid schiff (PAS) or Gordon Sweet stains.
Myeloablative regimen
Seven days after PBS (control), AdRSVhuTPO or AdRSV␤gal injection, mice were subjected to a myeloablative regimen consisting of the combination of 5 Gy irradiation and a single intraperitoneal injection of 1.2 mg of carboplatin (Paraplatin, Bristol-Myers-Squibb, Princeton, NJ, USA).
Statistical analysis
Means ± s.d. were calculated. Differences between AdRSVhuTPO and PBS groups were examined for statistical significance by Student's t test. A P value р 0.05 was considered to indicate statistical significance.
